![Meghan Thomas](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Meghan Thomas is currently Vice President-Clinical Development at Argenica Therapeutics Ltd. since 2022.
Formerly, Dr. Thomas was Vice President-Clinical Programs & Operations at Zelira Therapeutics Ltd. Education includes undergraduate and doctorate degrees from The University of Western Australia and an undergraduate degree from the University of Edith Cowan.
| Sociétés | Poste | Début |
|---|---|---|
| ARGENICA THERAPEUTICS LIMITED | Directeur Technique/Scientifique/R&D | 04/04/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
| ZELIRA THERAPEUTICS LIMITED | Directeur des opérations | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
The University of Western Australia
 The University of Western Australia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Edith Cowan
 University of Edith Cowan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zelira Therapeutics Ltd.
 Zelira Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Manufactures and supplies cannabinoid-based medicines for the treatment of human diseases and disorders | Health Technology |
Argenica Therapeutics Ltd.
 Argenica Therapeutics Ltd. BiotechnologyHealth Technology Develops novel neuro protective therapeutics to reduce brain damage | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
